Pain in the cancer patient: Different pain characteristics CHANGE pharmacological treatment requirements

Current Medical Research and Opinion

Volumn 30, Issue 9, 2014, Pages 1895-1908

  Müller Schwefe, Gerhard ^a   Ahlbeck, Karsten ^b   Aldington, Dominic ^c   Alon, Eli ^d   Coaccioli, Stefano ^e   Coluzzi, Flaminia ^f   Huygen, Frank ^g   Jaksch, Wolfgang ^h   Kalso, Eija ⁱ   Kocot Keopska, Magdalena ^j   Kress, Hans Georg ^k   Mangas, Ana Cristina ^l   Ferri, Cesar Margarit ^m   Morlion, Bart ⁿ   Nicolaou, Andrew ^o   Hernández, Concepción Pérez ^p   Pergolizzi, Joseph ^q,r   Schäfer, Michael ^s   Sichère, Patrick ^t  

^a Schmerz und Palliativzentrum   (Germany)

^b ST GÖRAN S HOSPITAL   (Sweden)

^c BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e Santa Maria General Hospital   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h WILHELMINEN HOSPITAL   (Austria)

ⁱ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^j JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^k MEDICAL UNIVERSITY OF VIENNA   (Austria)

^l Hospital de Santo Andre   (Portugal)

^m HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

ⁿ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^o ST GEORGE S HOSPITAL   (United Kingdom)

^p HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^q JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r Naples Anesthesia and Pain Associates   (United States)

^s CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^t Hôpitaux Universitaires de Paris Seine Saint Denis   (France)

more..

Author keywords

Breakthrough pain; Causative mechanisms; Chemotherapy induced neuropathic pain; Fast acting fentanyl formulations; Multidisciplinary approach; Opioids; Under treatment

Indexed keywords

ANALGESIA; COMPLICATION; HUMAN; NEOPLASM; PAIN; PAIN MEASUREMENT; PALLIATIVE THERAPY; PROCEDURES;

HUMANS; NEOPLASMS; PAIN; PAIN MANAGEMENT; PAIN MEASUREMENT; PALLIATIVE CARE;

EID: 84906837545     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.925439     Document Type: Article

References (116)

1. Breivik H, Cherny N, Collett B, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 2009;20:1420-33
2. Pharo GH, Zhou L. Pharmacologic management of cancer pain. J Am Osteopath Assoc 2005;105(11 Suppl 5):S21-8
3. European Society for Medical Oncology Minimum Clinical Recommendations for the management of cancer pain. Ann Oncol 2005;16(Suppl 1):i83-i85.
4. Foley KM. How well is cancer pain treated? Palliat Med 2011;25:398-401.
5. Lin C-C, Lai Y-L, Ward SE. Effect of cancer pain on performance status, mood states, and level of hope among Taiwanese cancer patients. J Pain Symptom Manage 2003;25:29-37
6. World Health Organization. Cancer Pain Relief. Geneva: World Health Organization, 1986.
7. Hsieh RK. Pain control in Taiwanese patients with cancer: a multicenter, patient-oriented survey. J Formos Med Assoc 2005;104:913-19.
8. Kuo PY, Yen JTC, Parker GM, et al. The prevalence of pain in patients attending sarcoma outpatient clinics. Sarcoma 2011;2011:813483
9. Fisch MJ, Lee J-W, Weiss M, et al. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol 2012;30:1980-8
10. Lodish H, Berk A, Zipursky SL, et al. Molecular Cell Biology, 4th edn. New York: W.H. Freeman, 2000
11. Schmidt BL, Hamamoto DT, Simone DA, Wilcox GL. Mechanism of cancer pain. Mol Interv 2010;10:164-78
12. Gokin AP, Fareed MU, Pan HL, et al. Local injection of endothelin-1 produces pain-like behavior and excitation of nociceptors in rats. J Neurosci 2001;21:5358-66
13. Hans G, Deseure K, Robert D, De Hert S. Neurosensory changes in a human model of endothelin-1 induced pain: a behavioral study. Neurosci Lett 2007;418:117-21
14. Davar G. Endothelin-1 and metastatic cancer pain. Pain Med 2001;2:24-7
15. Bortsov AV, Millikan RC, Belfer I, et al. m-opioid receptor gene Aa118G polymorphism predicts survival in patients with breast cancer. Anesthesiology 2012;116:896-902
16. Barki-Harrington L, Daaka Y. Bradykinin induced mitogenesis of androgen independent prostate cancer cells. J Urol 2001;165:2121-5
17. Fujita M, Andoh T, Ohashi K, et al. Roles of kinin B1 and B2 receptors in skin cancer pain produced by orthotopic melanoma inoculation in mice. Eur J Pain 2010;14:588-94
18. Andoh T, Akira A, Saiki I, Kuraishi Y. Bradykinin increases the secretion and expression of endothelin-1 through kinin B2 receptors in melanoma cells. Peptides 2010;31:238-41
19. Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br J Pharmacol 1997;121:417-24
20. Wacnik PW, Eikmeier LJ, Simone DA, et al. Nociceptive characteristics of tumor necrosis factor-alpha in naive and tumor-bearing mice. Neuroscience 2005;132:479-91
21. Constantin CE, Mair N, Sailer CA, et al. Endogenous tumor necrosis factor alpha (TNFalpha) requires TNF receptor type 2 to generate heat hyperalgesia in a mouse cancer model. J Neurosci 2008;28: 5072-81
22. Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30:1073-81
23. Zhu Z, Friess H, diMola FF, et al. Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol 1999;17:2419-28
24. Ma J, Jiang Y, Jiang Y, et al. Expression of nerve growth factor and tyrosine kinase receptor A and correlation with perineural invasion in pancreatic cancer. J Gastroenterol Hepatol 2008;23:1852-9
25. Kolokythas A, Cox DP, Dekker N, Schmidt BL. Nerve growth factor and tyrosine kinase A receptor in oral squamous cell carcinoma: is there an association with perineural invasion? J Oral Maxillofac Surg 2010;68:1290-5
26. Shen F-Z, Zhang B-Y, Feng Y-J, et al. Current research in perineural invasion of cholangiocarcinoma. J Exp Clin Canc Res 2010;29:24
27. Johnston M, Yu E, Kim J. Perineural invasion and spread in head and neck cancer. Expert Rev Anticancer Ther 2012;12:359-71
28. Liebig C, Ayala G, Wilks JA, et al. Perineural invasion in cancer. Cancer 2009;115:3379-91
29. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997;69:1-18
30. Koutsilieris M. Skeletal metastases in advanced prostate cancer: cell biology and therapy. Crit Rev Oncol Hematol 1995;18:51-64
31. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281:1591-7
32. Msaouel P, Pissimissis N, Halapas A, et al. Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Pract Res Clin Endocrinol Metab 2008;22:341-55
33. Vakaet LAM-L, Boterberg T. Pain control by ionizing radiation of bone metastasis. Int J Dev Biol 2004;48:599-606
34. Smith HJ. Painful osseous metastases. Pain Physician 2011;14:E373-405
35. Cain DM, Wacnik PW, Turner M, et al. Functional interactions between tumor and peripheral nerve: changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain. J Neurosci 2001;21:9367-76
36. Yanagisawa Y, Furue H, Kawamata T, et al. Bone cancer induces a unique central sensitization through synaptic changes in a wide area of the spinal cord. Molecular Pain 2010;6:38
37. Woolf CJ. What is this thing called pain? J Clin Invest 2010;120:3742-4
38. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004;140:441-51
39. Forde G. Adjuvant analgesics for the treatment of neuropathic pain: evaluating efficacy and safety profiles. J Fam Pract 2007;56:3-12
40. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630-5
41. Morlion B. Pharmacotherapy of low back pain: targeting nociceptive and neuropathic pain components. Curr Med Res Opin 2011;27:11-33
42. Schenk M, Urnauer H, Schug SA, et al. Cancer Pain. In: Spies C, Schug SA, Jaehnichen G, et al, eds. Pocket Guide Pain Management. Berlin Heidelberg: Springer-Verlag, 2008:67-79
43. Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008;19:1985-91
44. Rustøen T, Moum T, Padilla G, et al. Predictors of quality of life in oncology outpatients with pain from bone metastasis. J Pain Symptom Manage 2005;30:234-42
45. Mantyh P. Bone cancer pain: causes, consequences, and therapeutic opportunities. Pain 2013;154(Suppl 1):S54-62
46. Portenoy RK. Treatment of cancer pain. Lancet 2011;377:2236-47
47. Fainsinger RL, Nekolaichuk C, Lawlor P, et al. An international multicentre validation study of a pain classification system for cancer patients. Eur J Cancer 2010;46:2896-904
48. Lasheen W, Walsh D, Sarhill N, Davis M. Intermittent cancer pain: clinical importance and an updated cancer pain classification. Am J Hosp Palliat Care 2010;27:182-6
49. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81
50. Margarit C, Juliá J, López R, et al. Breakthrough cancer pain-still a challenge. J Pain Res 2012;5:559-66
51. Breuer B, Fleishman SB, Cruciani RA, et al. Medical oncologists' attitudes and practice in cancer pain management: a national survey. J Clin Oncol 2011;29:4769-75
52. Stockler MR, Wilcken NRC. Why is management of cancer pain still a problem? J Clin Oncol 2012;30:1907-8
53. Peng WL, Wu GJ, Sun WZ, et al. Multidisciplinary management of cancer pain: a longitudinal retrospective study on a cohort of end-stage cancer patients. J Pain Symptom Manage 2006;32:444-52
54. Buga S, Sarria JE. The management of pain in metastatic bone disease. Cancer Control 2012;19:154-66
55. Varrassi G, Müller-Schwefe G, Pergolizzi J, et al. Pharmacological treatment for chronic pain-the need for CHANGE. Curr Med Res Opin 2010;26:1055-69
56. Müller-Schwefe G, Jaksch W, Morlion B, et al. Make a CHANGE: optimising communication and pain management decisions. Curr Med Res Opin 2010;27:481-8
57. Stevens RA, Ghazi SM. Routes of opioid analgesic therapy in the management of cancer pain. Cancer Control 2000;7(2):132-41
58. Kress HG, von der Laage D, Hoerauf KH, et al. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain. J Pain Symptom Manage 2008;36:268-79
59. Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009;13:219-30
60. Heiskanen T, Mätzke S, Haakana S, et al. Transdermal fentanyl in cachectic cancer patients. Pain 2009;144:218-22
61. Moulin DE, Kreeft JH, Murray-Parsons N, et al. Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet 1991;337:465-8
62. Kress HG, Simpson KH, Marchettini P, et al. Intrathecal therapy: what has changed with the introduction of ziconotide. Pain Pract 2009;9:338-47
63. Raffaeli W, Sarti D, Demartini L, et al; and Italian Ziconotide Group. Italian registry on long-term intrathecal ziconotide treatment. Pain Phys 2011;14:15-24
64. Smith HS, Deer TR, Singh V, et al. Intrathecal drug delivery. Pain Phys 2008;11:S89-104
65. Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS. JAMA 2004;291:63-70
66. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004;56:387-437
67. Coluzzi F, Di Bussolo E, Mandatori I, Mattia C. Bone metastatic disease: taking aim at new therapeutic targets. Curr Med Chem 2011;18:3093-115
68. Coluzzi F, Mandatori I, Mattia C. Emerging therapies in metastatic bone pain. Expert Opin Emerg Drugs 2011;16:441-58
69. National Cancer Institute at the National Institutes of Health. Management with Drugs. Last updated 27th February 2012. Available at: http://www.cancer. gov/cancertopics/pdq/supportivecare/pain/Patient/page4 [Last accessed 4 April 2013]
70. Caraceni A, Hanks G, Kaasa S, et al; on behalf of the European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13:e58-68
71. Christo PJ, Mazloomdoost D. Cancer pain and analgesia. Ann NY Acad Sci 2008;1138:278-98
72. Tay W, Ho KY. The role of interventional therapies in cancer pain management. Ann Acad Med Singapore 2009;38:989-97
73. Bates T. A review of local radiotherapy in the treatment of bone metastases and cord compression. Int J Radiat Oncol Biol Phys 1992;23:217-21
74. Maher EJ. The use of palliative radiotherapy in the management of breast cancer. Eur J Cancer 1992;28:706-10
75. Bae SH, Park W, Choi DH, et al. Palliative radiotherapy in patients with a symptomatic pelvic mass of metastatic colorectal cancer. Radiation Oncology 2011;6:52
76. Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2: management. Pharm Ther 2005;30:354-61
77. Davies AN, Dickman A, Reid C, et al. The management of cancer-related break-through pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009;13:331-8
78. Caraceni A, Martini C, Zecca E, Portenoy RK. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004;18:177-83
79. Davies A. Current thinking in cancer breakthrough pain management. Eur J Palliat Care 2005;12(Suppl):4-6
80. Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005;9:195-206
81. Portenoy RK, Payne D, Jacobson P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81:129-34
82. Gómez-Batiste X, Madrid F, Moreno F, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage 2002;24:45-52
83. Saini A, Tucci M, Tampellini M, et al. Circadian variation of breakthrough pain in cancer patients. Eur J Pain 2012: published online 19 June 2012, doi: 10.1002/j.1532-2149.2012.00184.x
84. Mercadante S, Costanzo BV, Fusco F, et al. Breakthrough pain in advanced cancer patients followed at home: a longitudinal study. J Pain Symptom Manage 2009;38:554-60
85. Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage 2013;46:619-28
86. Davies A, Vriens J, Kennett A, McTaggart M. An observational study of oncology patients' utilization of breakthrough pain medication. J Pain Symptom Manage 2008;35:406-11
87. Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009;25:2877-85
88. Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007;5:327-34
89. Darwish M, Kirby M, Robertson P, et al. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol 2007;47:343-50
90. Kress HG, Orońska A, Kaczmarek Z, et al. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 mg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther 2009;31:1177-91
91. Kaasa S, Moksnes K, Nolte T, et al. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manag 2010;6:17-26
92. Twycross R, Prommer EE, Mihalyo M, Wilcock A. Fentanyl (transmucosal). J Pain Symptom Manage 2012;44:131-49
93. Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev 2006;(1):CD004311
94. Zeppetella G. Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project. Palliative Med 2001;25:516-24
95. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001;91:123-30
96. Beijers AJM, Jongen JLM, Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med 2012;70:18-25
97. Warwick RA, Hanani M. The contribution of satellite glial cells to chemotherapy-induced neuropathic pain. Eur J Pain 2013;17:571-80
98. Kweekel DM, Gelderblom H, Guchelaar H-J. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 2005;31:90-105
99. Hausheer FH, Schilsky RL, Bain S, et al. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 2006;33:15-49
100. Balayssac D, Ferrier J, Descoeur J, et al. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf 2011;10:407-17
101. Hausheer FH, Kochat H, Parker AR, et al. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent. Cancer Chemother Pharmacol 2003;52(Suppl):S3-15
102. Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013;309:1359-67
103. Durand JP, Deplanque G, Montheil V, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 2011;23:200-5
104. Barton DL, Wos EJ, Qin R, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 2011;19:833-41
105. Smith TJ, Coyne PJ, Parker GL, et al. Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare) for chemotherapy-induced peripheral neuropathy. J Pain Symptom Manage 2010;40:883-91
106. Hammack JE, Michalak JC, Loprinzi CL, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 2002;98:195-203
107. Kautio AL, Haanpä ä M, Saarto T, Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 2008;35:31-9
108. Bianchi G, Vitali G, Caraceni A, et al. Symptomatic and neurophysiological responses of paclitaxel-or cisplatin-induced neuropathy to oral acetyl-Lcarnitine. Eur J Cancer 2005;41:1746-50
109. Storey DJ, Colvin LA, Scott AC, et al. Treatment of chemotherapy-induced peripheral neuropathy (CIPN) with topical menthol: a phase I study. J Clin Oncol 2010;28(15):Suppl 9129
110. Nassini R, Benemei S, Fusi C, et al. Transient receptor potential channels in chemotherapy-induced neuropathy. Open Pain J 2013;6(Suppl 1):127-36
111. Hojsted J, Sjogren P. Addiction to opioids in chronic pain patients: a literature review. Eur J Pain 2007;11:490-518
112. Koyyalagunta D, Bruera E, Aigner C, et al. Risk stratification of opioid misuse among patients with cancer pain using the SOAPP-SF. Pain Med 2013;14:667-75
113. Childers JW, Arnold RM. "I feel uncomfortable 'calling a patient out"': Educational needs of palliative medicine fellows in managing opioid misuse. J Pain Symptom Manage 2012;43:253-60
114. Passik SD, Theobald DE. Managing addiction in advanced cancer patients: why bother? J Pain Symptom Manage 2000;19:229-34
115. Turk DC, Stieg RL. Chronic pain: the necessity of interdisciplinary communication. Clin J Pain 1987;3:163-7
116. Kress HG. The importance of putting pain on the curricula in medical schools in Europe. J Pain Palliat Care Pharmacother 2013; 27:182-4